LAVAL, Quebec, Dec. 4, 2017 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (“Valeant” or the “Company”) announced today that it has launched an offering of $1,000,000,000 aggregate principal amount of unsecured senior notes due 2025 (the “Notes”)….
